Sucralfate (sucralfate oral) NDC 42291-781

NDC codes

FDA NDC Directory

Product NDC (as listed)42291-781Labeler and product segments. Claims need a package NDC.

Product NDC at billing width42291-0781Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
42291-781-42	42291078142	420 mL in 1 BOTTLE (42291-781-42)Marketed from Apr 16, 2021

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Sucralfate
Generic name (nonproprietary): sucralfate oral
Active ingredients: Sucralfate — 1 g/10mL
Dosage form: Suspension
Route: Oral
Labeler: AvKARE
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 209356
Marketing start: Apr 16, 2021
Listing expires: Dec 31, 2026
Other FDA classes: Organometallic Compounds (Chemical structure)
Identifiers: Product ID 42291-781_45107b4b-d201-c653-e063-6294a90a122dSPL ID 45107b4b-d201-c653-e063-6294a90a122dSPL set ID c019bf24-8273-8d2f-e053-2a95a90aec98RxCUI 313123UNII XX73205DH5
Pharmacologic class: Aluminum Complex

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N442291078142 followed by a unit qualifier and the quantity

Package 42291-0781-42. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 3, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Sucralfate Oral Suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 209356

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 209356
Product	Strength	Form · route	Labeler	Product NDC
Sucralfatesucralfate oral	Sucralfate 1 g/10mL	SuspensionOral	Cardinal Health 107, LLC	55154-4348
Sucralfatesucralfate oral	Sucralfate 1 g/10mL	SuspensionOral	AvPAK	50268-745
Sucralfatesucralfate oral	Sucralfate 1 g/10mL	SuspensionOral	Amneal Pharmaceuticals LLC	65162-062
Sucralfatesucralfate oral	Sucralfate 1 g/10mL	SuspensionOral	Precision Dose, Inc.	68094-041